Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (Octagam 5%®) cannot be endorsed for use within NHS Wales for the treatment of chronic inflammatory demyelinating polyneuropathy in adults, and children and adolescents (0–18 years). |
||
|
||
Medicine details |
||
| Medicine name | human normal immunoglobulin (Octagam 5%®) | |
| Formulation | 50 mg/ml solution for infusion | |
| Reference number | 3368 | |
| Indication | Treatment of chronic inflammatory demyelinating polyneuropathy in adults, and children and adolescents (0–18 years) |
|
| Company | Octapharma AG | |
| BNF chapter | Immunological products & vaccines | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 30/01/2017 | |